Get Premium to unlock powerful stock data
Deciphera Pharmaceuticals Inc logo

Deciphera Pharmaceuticals Inc $ 8.47 0.43 (5.35%)

Avg Vol (1m):
Market Cap $:
495.33 Mil
Enterprise Value $:
157.75 Mil
PE Ratio:
At Loss
PB Ratio:
Warning! GuruFocus has detected 3 Severe warning signs with DCPH. Click here to check it out.
Also Trade In: Germany
10Y: -% Above Low: +NaN% Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for DCPH (Deciphera Pharmaceuticals Inc) from 2017 to Jan 24 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Deciphera Pharmaceuticals stock (DCPH) PE ratio as of Jan 24 2022 is 0. More Details

Deciphera Pharmaceuticals PE Ratio (TTM) Chart


Deciphera Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1094
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 13
Deciphera Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-01-25At Loss 2021-11-22At Loss
2022-01-21At Loss 2021-11-19At Loss
2022-01-20At Loss 2021-11-18At Loss
2022-01-19At Loss 2021-11-17At Loss
2022-01-18At Loss 2021-11-16At Loss
2022-01-17At Loss 2021-11-15At Loss
2022-01-14At Loss 2021-11-12At Loss
2022-01-13At Loss 2021-11-11At Loss
2022-01-12At Loss 2021-11-10At Loss
2022-01-11At Loss 2021-11-09At Loss
2022-01-10At Loss 2021-11-08At Loss
2022-01-07At Loss 2021-11-05At Loss
2022-01-06At Loss 2021-11-04At Loss
2022-01-05At Loss 2021-11-03At Loss
2022-01-04At Loss 2021-11-02At Loss
2022-01-03At Loss 2021-11-01At Loss
2021-12-31At Loss 2021-10-29At Loss
2021-12-30At Loss 2021-10-28At Loss
2021-12-29At Loss 2021-10-27At Loss
2021-12-28At Loss 2021-10-26At Loss
2021-12-27At Loss 2021-10-25At Loss
2021-12-24At Loss 2021-10-22At Loss
2021-12-23At Loss 2021-10-21At Loss
2021-12-22At Loss 2021-10-20At Loss
2021-12-21At Loss 2021-10-19At Loss
2021-12-20At Loss 2021-10-18At Loss
2021-12-17At Loss 2021-10-15At Loss
2021-12-16At Loss 2021-10-14At Loss
2021-12-15At Loss 2021-10-13At Loss
2021-12-14At Loss 2021-10-12At Loss
2021-12-13At Loss 2021-10-11At Loss
2021-12-10At Loss 2021-10-08At Loss
2021-12-09At Loss 2021-10-07At Loss
2021-12-08At Loss 2021-10-06At Loss
2021-12-07At Loss 2021-10-05At Loss
2021-12-06At Loss 2021-10-04At Loss
2021-12-03At Loss 2021-10-01At Loss
2021-12-02At Loss 2021-09-30At Loss
2021-12-01At Loss 2021-09-29At Loss
2021-11-30At Loss 2021-09-28At Loss
2021-11-29At Loss 2021-09-27At Loss
2021-11-26At Loss 2021-09-24At Loss
2021-11-25At Loss 2021-09-23At Loss
2021-11-24At Loss 2021-09-22At Loss
2021-11-23At Loss 2021-09-21At Loss

Deciphera Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Deciphera Pharmaceuticals Inc logo

Business Description

Healthcare » Drug Manufacturers » NAICS : 325412 SIC : 2834
Traded in other countries / regions
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.